These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20044916)

  • 41. Principles and therapeutic relevance for targeting mitochondria in aging and neurodegenerative diseases.
    Serviddio G; Romano AD; Cassano T; Bellanti F; Altomare E; Vendemiale G
    Curr Pharm Des; 2011; 17(20):2036-55. PubMed ID: 21718251
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pediatric use of tetracyclines: focus on neurodevelopmental effects.
    Inta I; Hoffmann GF; Bettendorf M
    Pediatr Res; 2017 Nov; 82(5):725-726. PubMed ID: 28700569
    [No Abstract]   [Full Text] [Related]  

  • 43. Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection.
    Stone TW; Forrest CM; Darlington LG
    FEBS J; 2012 Apr; 279(8):1386-97. PubMed ID: 22248239
    [TBL] [Abstract][Full Text] [Related]  

  • 44. OPC 14117.
    Drugs R D; 1999 Jan; 1(1):34-5. PubMed ID: 10565980
    [No Abstract]   [Full Text] [Related]  

  • 45. A Brief Review on the Neuroprotective Mechanisms of Vitexin.
    Lima LKF; Pereira SKS; Junior RDSS; Santos FPDS; Nascimento AS; Feitosa CM; Figuerêdo JS; Cavalcante ADN; Araújo ECDC; Rai M
    Biomed Res Int; 2018; 2018():4785089. PubMed ID: 30627560
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of Precision Small-Molecule Proneurotrophic Therapies for Neurodegenerative Diseases.
    Janssens J; Lu D; Ni B; Chadwick W; Siddiqui S; Azmi A; Etienne H; Jushaj A; van Gastel J; Martin B; Maudsley S
    Vitam Horm; 2017; 104():263-311. PubMed ID: 28215298
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapeutic potential of PACAP for neurodegenerative diseases.
    Yang R; Jiang X; Ji R; Meng L; Liu F; Chen X; Xin Y
    Cell Mol Biol Lett; 2015 Jun; 20(2):265-78. PubMed ID: 26204407
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Protection of nerve cells with drugs. The Institute for Pharmacology and Toxicology in the Pharmacy Department of Philipps University Marburg].
    Schwarz S
    Med Monatsschr Pharm; 2002 Jul; 25(7):226-8. PubMed ID: 12148234
    [No Abstract]   [Full Text] [Related]  

  • 49. Melatonin as a structural template in the development of novel drugs for neurodegenerative disorders.
    Korábečný J
    Ceska Slov Farm; 2018; 67(2):51-58. PubMed ID: 30189733
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Curcumin and neurodegenerative diseases: a perspective.
    Darvesh AS; Carroll RT; Bishayee A; Novotny NA; Geldenhuys WJ; Van der Schyf CJ
    Expert Opin Investig Drugs; 2012 Aug; 21(8):1123-40. PubMed ID: 22668065
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vitamin K: a structural basis for the design of novel neuroprotective agents?
    Chou CJ; Inks ES; Josey BJ
    Future Med Chem; 2013 May; 5(8):857-60. PubMed ID: 23682563
    [No Abstract]   [Full Text] [Related]  

  • 52. Effects of Ashwagandha (roots of Withania somnifera) on neurodegenerative diseases.
    Kuboyama T; Tohda C; Komatsu K
    Biol Pharm Bull; 2014; 37(6):892-7. PubMed ID: 24882401
    [TBL] [Abstract][Full Text] [Related]  

  • 53. TNFR2 - target for therapeutics against neurodegenerative diseases?
    Nijholt IM; Granic I; Luiten PG; Eisel UL
    Adv Exp Med Biol; 2011; 691():567-73. PubMed ID: 21153362
    [No Abstract]   [Full Text] [Related]  

  • 54. Pharmacological Alternatives for the Treatment of Neurodegenerative Disorders: Wasp and Bee Venoms and Their Components as New Neuroactive Tools.
    Silva J; Monge-Fuentes V; Gomes F; Lopes K; dos Anjos L; Campos G; Arenas C; Biolchi A; Gonçalves J; Galante P; Campos L; Mortari M
    Toxins (Basel); 2015 Aug; 7(8):3179-209. PubMed ID: 26295258
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders.
    Geldenhuys WJ; Van der Schyf CJ
    Expert Opin Drug Discov; 2013 Feb; 8(2):115-29. PubMed ID: 23231597
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pathologically activated therapeutics for neuroprotection.
    Lipton SA
    Nat Rev Neurosci; 2007 Oct; 8(10):803-8. PubMed ID: 17882256
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapeutic Role and Drug Delivery Potential of Neuroinflammation as a Target in Neurodegenerative Disorders.
    Singh A; Chokriwal A; Sharma MM; Jain D; Saxena J; Stephen BJ
    ACS Chem Neurosci; 2017 Aug; 8(8):1645-1655. PubMed ID: 28719178
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Management of glaucoma as a neurodegenerative disease.
    Jutley G; Luk SM; Dehabadi MH; Cordeiro MF
    Neurodegener Dis Manag; 2017 Apr; 7(2):157-172. PubMed ID: 28540772
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neurotrophic molecules: strategies for designing effective therapeutic molecules in neurodegeneration.
    Skaper SD; Walsh FS
    Mol Cell Neurosci; 1998 Nov; 12(4-5):179-93. PubMed ID: 9828084
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Australian neuroscience in 2006--highlights from the scientific meeting.
    Doggrell SA
    Drug News Perspect; 2006 Jun; 19(5):300-6. PubMed ID: 16941052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.